Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | See Remarks | March 09, 2026 | March 11, 2026 |
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | See Remarks | May 26, 2020 | May 28, 2020 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date March 09, 2026 · Filed March 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.03 · Expires 2036-03-09 | Direct | 37,485 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 37,485 · Balance 37,485 F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Global Blood Therapeutics, Inc.
Report date May 26, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154 |
Ending reported balance
After 2020-05-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-26 · Exercise / conversion · Acquired 2,700 · Balance 2,854 Row 2 · 2020-05-26 · Sale · Disposed 2,700 · Balance 154 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.75 · Expires 2027-02-28 | Direct | 900 |
Reported balance
After 2020-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-26 · Exercise / conversion · Disposed 2,700 · Balance 900 F1: The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Tango Therapeutics, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,500 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,000 · Balance 16,500 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.22 · Expires 2036-06-05 | Direct | 25,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 25,000 · Balance 25,000 F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2019 Filed Aug 5, 2019 17:06 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-021013 · doc4.xml · derivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:06 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 1,060 | $54.25 | $57,505.00 |
DisclosureSEC source: 0000899243-19-021013 · doc4.xml · nonDerivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,456 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,062 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:06 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 3,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-021013 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 31, 2019 Filed Aug 5, 2019 17:06 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 226 | $36.68 | $8,289.68 |
DisclosureSEC source: 0000899243-19-021013 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006308 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 104 | $53.48 | $5,561.92 |
DisclosureSEC source: 0000899243-19-006308 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,228 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 300 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006308 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 17:29 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 354 | $50.45 | $17,860.36 |
DisclosureSEC source: 0000899243-19-003661 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032 F1 · balance_after: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:53 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002667 · doc4.xml · derivative · entry 5 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:53 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002667 · doc4.xml · derivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:53 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0000899243-19-002667 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2029-01-31 F3 · derivative.exercise_date: The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:53 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 307 | $48.44 | $14,871.08 |
DisclosureSEC source: 0000899243-19-002667 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,477 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 750 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:53 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-002667 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2019 Filed Feb 14, 2019 17:29 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 354 | $36.68 | $12,984.72 |
DisclosureSEC source: 0000899243-19-003661 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,386 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:05 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 104 | $48.95 | $5,090.80 |
DisclosureSEC source: 0000899243-18-023971 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034 Read SEC document |
| September 01, 2018 Filed Sep 6, 2018 20:05 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-023971 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in eight equal semi-annual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 01, 2018 Filed Sep 6, 2018 20:05 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-023971 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 300 | $49.19 | $14,756.40 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · nonDerivative · entry 6 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 838 Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · derivative · entry 8 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,205 Underlying: Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · derivative · entry 7 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,205 Underlying: Common Stock · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,500 | $50.01 | $75,020.25 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · nonDerivative · entry 5 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138 F2 · price: Represents the weighted average sale price of the shares sold ranging from $50.0000 to $50.0304 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,000 | $22.00 | $22,000.00 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · nonDerivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 500 | $22.00 | $11,000.00 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · nonDerivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 204 | $49.97 | $10,193.68 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 17:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-021424 · doc4.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in eight equal semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. F2 · derivative.expiration_date: The RSUs vest in eight equal semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 17:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-021424 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 01, 2018 Filed Feb 14, 2019 17:26 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 258 | $43.52 | $11,228.16 |
DisclosureSEC source: 0000899243-19-003657 · doc5.xml · nonDerivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032 Read SEC document |
| July 31, 2018 Filed Aug 20, 2018 20:25 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 204 | $35.53 | $7,248.12 |
DisclosureSEC source: 0000899243-18-022840 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 18:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,295 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019717 · doc4.xml · derivative · entry 6 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,705 Underlying: Common Stock · 2,295 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 18:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 2,295 | $44.27 | $101,608.83 |
DisclosureSEC source: 0000899243-18-019717 · doc4.xml · nonDerivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388 Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 18:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,295 | $22.00 | $50,490.00 |
DisclosureSEC source: 0000899243-18-019717 · doc4.xml · nonDerivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 18:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019717 · doc4.xml · derivative · entry 5 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 1,000 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 18:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,000 | $44.01 | $44,005.00 |
DisclosureSEC source: 0000899243-18-019717 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388 Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 18:10 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,000 | $22.00 | $22,000.00 |
DisclosureSEC source: 0000899243-18-019717 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2018 Filed Feb 14, 2019 17:26 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 187 | $44.88 | $8,392.56 |
DisclosureSEC source: 0000899243-19-003657 · doc5.xml · nonDerivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290 Read SEC document |
| March 15, 2018 Filed Feb 14, 2019 17:26 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 510 | $54.68 | $27,886.80 |
DisclosureSEC source: 0000899243-19-003657 · doc5.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,477 Read SEC document |
| March 05, 2018 Filed Mar 5, 2018 17:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 99 | $60.35 | $5,974.65 |
DisclosureSEC source: 0000899243-18-006362 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006362 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006362 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. Read SEC document |
| February 01, 2018 Filed Feb 13, 2018 21:28 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-003750 · doc4.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in eight semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. Read SEC document |
| February 01, 2018 Filed Feb 13, 2018 21:28 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $59.60 | $0.00 |
DisclosureSEC source: 0000899243-18-003750 · doc4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: The Stock Option becomes exercisable in sixteen equal quarterly installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 31, 2018 Filed Feb 14, 2019 17:26 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 510 | $21.34 | $10,883.40 |
DisclosureSEC source: 0000899243-19-003657 · doc5.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,987 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 01, 2017 Filed Feb 13, 2018 21:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-003749 · doc5.xml · derivative · entry 6 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. Read SEC document |
| September 01, 2017 Filed Feb 13, 2018 21:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 113 | $30.30 | $3,423.90 |
DisclosureSEC source: 0000899243-18-003749 · doc5.xml · nonDerivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187 Read SEC document |
| September 01, 2017 Filed Feb 13, 2018 21:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-003749 · doc5.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. Read SEC document |
| August 02, 2017 Filed Feb 13, 2018 21:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,552 | $27.23 | $42,260.96 |
DisclosureSEC source: 0000899243-18-003749 · doc5.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Includes 1,552 shares acquired under the Issuer's Employee Stock Purchase Plan on July 31, 2017 in a transaction exempt under Rule 16b-3. Read SEC document |
| March 01, 2017 Filed Feb 13, 2018 21:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 2,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-003749 · doc5.xml · derivative · entry 5 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of GBT common stock. Read SEC document |
| March 01, 2017 Filed Feb 13, 2018 21:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 3,600 | $0.00 Strike: $29.75 | $0.00 |
DisclosureSEC source: 0000899243-18-003749 · doc5.xml · derivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2026-02-28 F3 · derivative.exercise_date: The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.